Weekly RSV Vaccination Dashboard

About

The Weekly RSV Vaccination Dashboard is designed to share preliminary weekly in-season RSV vaccination information, including vaccination coverage estimates and intent for vaccination, using a variety of data sources including surveys, healthcare claims databases, electronic medical records, and immunization information systems (IISs). The Dashboard will be updated weekly as new data become available. These estimates might differ from estimates that could be published after the end of each season using different analytic methods or based on data sources not available during the season. Please email to share any feedback (VaxView@cdc.gov).
Weekly RSV Vaccination Dashboard

Data Summary

Data Updates

Next data updates are scheduled for April 15, 2026, and May 20, 2026, during 11 a.m. - 1 p.m. ET. Data, visuals, and/or features may be changing and may not match their final state during this time.

RSV vaccination coverage estimates among adults 75 years and older and 50─74 years with high-risk conditions for RSV are based on self-reported data from CDC's National Immunization Survey-Fall Respiratory Virus Module (FRVM). Data collection for the NIS-FRVM for the 2025─26 season ended on February 22, 2026. Data and charts are available.

  • As of February 22, 2026, 43.2% (95% Confidence Interval: 41.0%─45.4%) of adults 75 years and older and 32.8% (30.4%─35.3%) of adults 50─74 years with a high-risk condition for RSV reported having ever received an RSV vaccine.

RSV vaccination coverage estimates among adults 75 years and older as of the end of February 2026 are based on IIS data submitted to CDC by 13 immunization awardee jurisdictions. The coverage of some Pacific Island jurisdictions may reflect vaccination program activities aligned with regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.). Data and charts are available.

  • Among the currently reporting eight state and city IIS jurisdictions, RSV vaccination coverage among adults 75 years and older ranged from 19.4% to 46.3%. Among five U.S. territorial and affiliated island jurisdictions, coverage ranged from 0% to 15.7%.

RSV vaccination coverage among Medicare fee-for-service beneficiaries 75 years and older and enrolled in a Part D plan is assessed using data files from the Medicare Fee-For-Service administrative claims data managed by the Centers for Medicare & Medicaid Services. Data and charts are available.

  • As of January 31, 2026, an estimated 36.9% of Medicare fee-for-service beneficiaries 75 years and older enrolled in a Part D plan were vaccinated.
  • Vaccination coverage was highest among White, non-Hispanic beneficiaries (37.9%) and lowest among Hispanic beneficiaries (14.9%).

IQVIA measures RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians' medical offices for all adults 50 years and older (regardless of presence of high-risk conditions for RSV), based on healthcare claims data. Data and charts are available.

  • During August 12, 2023, through February 28, 2026, in retail pharmacies and physicians' medical offices combined:
    • An estimated ~305,611 doses of RSV vaccines were administered among all adults 50-59 years.
    • An estimated ~9.48 million doses of RSV vaccines were administered among all adults 60-74 years.
    • An estimated ~7.43 million doses of RSV vaccines were administered among all adults 75 years and older.

Estimates of RSV vaccination coverage for pregnant women 18─49 years are calculated using data from CDC's Vaccine Safety Datalink (VSD). VSD data includes electronic health records data from ten integrated health systems. Data and charts are available.

  • As of January 31, 2026, among women who were pregnant and at least 32 weeks' gestation since September 1, 2025, overall coverage with the RSV vaccine was 40.3%.
  • Vaccination coverage was highest among non-Hispanic Asian (53.7%) pregnant women and lowest among non-Hispanic Black (27.7%) pregnant women.

Monthly estimates of infant protection against RSV by maternal RSV vaccination or receipt of monoclonal antibody, as well as intent for monoclonal antibody receipt, reported by females 18─49 years with infants <8 months during the RSV season (born since April 1, 2025) are based on data from CDC’s National Immunization Survey-Fall Respiratory Virus Module (FRVM). Data collection for the NIS-FRVM for the 2025─26 season ended on February 22, 2026. Data and charts are available.

  • As of February 2026, among females with an infant born since April 1, 65.1% of infants were reported to be protected against RSV through either maternal immunization only (9.4%) or receipt of monoclonal antibody (55.7%); an additional 9.1% reported that they would definitely get monoclonal antibody for their infants.

Monoclonal antibody administration and coverage estimates among infants <8 months (born since April 1, 2025) as of the end of February 2026 are based on IIS data submitted to CDC by 13 immunization awardee jurisdictions. The coverage of some Pacific Island jurisdictions may reflect vaccination program activities aligned with regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.). Data and charts are available.

  • Among the currently reporting eight state and city IIS jurisdictions, monoclonal antibody coverage among infants <8 months (born since April 1) ranged from 34.2% to 52.5%.  Among five U.S. territorial and affiliated island jurisdictions, coverage ranged from 0% to 31.1%.

Data & Charts

Data & Charts

View available vaccination data using interactive maps, graphs, charts, and tables.

Archived Season Data & Charts

Prevent RSV

Adults 50 years and older and pregnant women can protect themselves from RSV.

Learn more about RSV.

Print
Content Source:
National Center for Immunization and Respiratory Diseases; Immunization Services Division